| http://www.w3.org/ns/prov#value | - Together, we create an impressive platform to commercialize new eye care and allergy products already under development.The transaction, which is expected to be accretive to Bausch + Lomb's EBITDA in the first year after close, is subject to regulatory approval and other customary closing conditions, including the approval of ISTA's shareholders.
|
